A New Treatment Option for NET Patients
March 26, 2025
The U.S. Food and Drug Administration (FDA) has approved cabozantinib for the treatment of previously
$39.8M
Million in NET research funding
50
Active Research
Projects
17
Countries with ongoing studies
The U.S. Food and Drug Administration (FDA) has approved cabozantinib for the treatment of previously
Chimeric Therapeutics is reporting early signs of efficacy in the world’s first clinical trial of
Neuroendocrine cancer researchers from around the world gathered in Krakow, Poland for the 22nd Annual
You can support a brighter future. Make a gift. Host an event. Or volunteer to help us advance our understanding of neuroendocrine tumors.
Learn about neuroendocrine tumor tests, treatments, and research. Find out about educational and inspirational events in the NET community.
NETRF hosts free patient and caregiver neuroendocrine tumor conferences to educate and empower individuals to be part of their care planning and live their best life.